Synthetic Blood International, Inc. (SYBD) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Synthetic Blood International, Inc. (SYBD)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Micro-Selector who wrote (12)	3/12/1999 11:32:00 AM
From: Micro-Selector	Read Replies (1) of 91

Info on SYBD competitor: *********************** Hemosol Cleared to Begin Multinational Phase III Trials of Blood Substitute Product Trials of Hemolink(TM) Will Begin in U.S. and U.K. in Patients Undergoing Coronary Artery Bypass Surgery TORONTO, March 11 /CNW/ - Hemosol Inc., a Canadian-based biopharmaceutical company, today announced it is cleared to move forward with Phase III trials in the U. S. and the U.K. using Hemolink(TM), its first blood substitute product. The initial Phase III trial will be conducted in patients undergoing coronary artery bypass grafting surgery (CABG). * deleted rest of release * HMSLF currently trades at $3.35.** For some reason though, I am unable to pull up a chart using any of my resources. Just thought this was interesting to note as we move toward final patent (per last news release) and new source of financing for SYBD to begin clinical trials (per Fledgling newsletter). Regards, Micro

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next